Requires certain information to be included in every pharmacy benefit manager's annual report to the superintendent such as the aggregated dollar amount of rebates, fees, price protection payments and any other payments the pharmacy benefit manager received from drug manufacturers through rebate contract, the amount of certain allocations, and information on rebate contracts.

This bill requires pharmacy benefit managers to include specific financial information in their annual reports to the state's superintendent. This includes details on rebates, fees, and payments they receive from drug manufacturers, as well as allocations and information on rebate contracts. The goal is to enhance transparency in the pharmaceutical industry.

Supporters of the bill argue that it will promote transparency and accountability among pharmacy benefit managers, ensuring that consumers and regulators understand the financial dynamics of drug pricing. By requiring detailed reporting, the bill aims to help identify potential savings for patients and improve the overall healthcare system.

Critics may argue that the bill places an unnecessary burden on pharmacy benefit managers, potentially leading to increased costs that could be passed on to consumers. They might also contend that the focus on financial reporting does not address the underlying issues of drug pricing and access to medications.